We will be contrasting the differences between Seres Therapeutics Inc. (NASDAQ:MCRB) and CRISPR Therapeutics AG (NASDAQ:CRSP) as far as institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Seres Therapeutics Inc.||4||0.02||41.01M||-2.34||0.00|
|CRISPR Therapeutics AG||55||0.00||34.37M||-3.74||0.00|
Table 1 shows top-line revenue, earnings per share and valuation of the two companies.
Table 2 demonstrates the return on assets, net margins and return on equity of Seres Therapeutics Inc. and CRISPR Therapeutics AG.
|Net Margins||Return on Equity||Return on Assets|
|Seres Therapeutics Inc.||1,113,615,380.44%||235.9%||-81.2%|
|CRISPR Therapeutics AG||62,948,717.95%||-50.9%||-39.8%|
Seres Therapeutics Inc. has a Current Ratio of 1.6 and a Quick Ratio of 1.6. Competitively, CRISPR Therapeutics AG’s Current Ratio is 15.8 and has 15.8 Quick Ratio. CRISPR Therapeutics AG’s better ability to pay short and long-term obligations than Seres Therapeutics Inc.
The table delivered features the ratings and recommendations for Seres Therapeutics Inc. and CRISPR Therapeutics AG.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Seres Therapeutics Inc.||0||0||0||0.00|
|CRISPR Therapeutics AG||0||0||4||3.00|
On the other hand, CRISPR Therapeutics AG’s potential downside is -8.11% and its average target price is $66.5.
Insider and Institutional Ownership
The shares of both Seres Therapeutics Inc. and CRISPR Therapeutics AG are owned by institutional investors at 61.9% and 50% respectively. About 0.4% of Seres Therapeutics Inc.’s share are held by insiders. On the other hand, insiders held about 2% of CRISPR Therapeutics AG’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Seres Therapeutics Inc.||-9%||-7.46%||-55.32%||-55.46%||-62.76%||-39.6%|
|CRISPR Therapeutics AG||3.15%||6.25%||30.58%||57.23%||7.51%||77.42%|
For the past year Seres Therapeutics Inc. has -39.6% weaker performance while CRISPR Therapeutics AG has 77.42% stronger performance.
Seres Therapeutics Inc. beats CRISPR Therapeutics AG on 6 of the 11 factors.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.